13F Pro Quality Score

33.3/100

Rank #2,234 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

67.7/100

Profitability

10.9/100

Balance Sheet

12.2/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

32.3/100

Revenue Scale

22.8/100

Dilution Risk

94.9/100

VALN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Valneva SE (VALN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VALN at 33.3/100 on a 32-signal composite quality model, placing it at rank #2,234 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (10.9) and balance sheet strength (12.2), which score below median versus the broader universe. Top institutional holders of VALN by reported 13-F value include Frazier Life Sciences Management, L.P., Novo Holdings A/S, GENERAL AMERICAN INVESTORS CO, based on the most recent SEC filings. VALN trades on the Nasdaq exchange and files with the SEC under CIK 1836564. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VALN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Valneva SE directly from SEC EDGAR. Valneva SE's 13F Pro composite quality score has ranged between 33 and 33 since 2026, currently 33.3 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

Fun facts about Valneva SE

Quirks, history, and lore behind VALN — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A European biotech company · small-cap · listed on Nasdaq · headquartered in France with major operations in Austria and Scotland.
  • 2
    The Numbers
    Revenue in the tens of millions of euros, with the company still largely in investment and development mode — profits are not yet the point.
  • 3
    The History
    Founded around 1999, it spent two decades quietly building a pipeline focused on infectious disease vaccines for which there are few or no existing approved options.
  • 4
    The Secret
    Its biggest near-win came when a COVID-19 vaccine partnership with the UK government collapsed in 2022 — a very public stumble that hammered its stock.
  • 5
    The Lore
    It won approval for the world's first and only chikungunya vaccine — a disease most people can't pronounce, let alone knew needed a vaccine.
  • 6
    The Giveaway
    This Franco-Austrian vaccine specialist also holds an approved travel vaccine against Japanese encephalitis and trades on Nasdaq under a ticker that matches its name almost letter for letter.
▶ Think you know your stocks? Play the Daily Ticker

Get alerted when VALN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Valneva SE including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put VALN on your watchlist

Track score changes the day Valneva SE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is VALN a good stock to buy?

13F Pro's AI-powered analysis of Valneva SE (VALN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VALN are available on the VALN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VALN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VALN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Valneva SE's investment landscape.